BPC-157: The Complete Research Protocol
Last Updated: February 3, 2026
Reading Time: 12 minutes
Disclaimer: This article is for educational and research purposes only. BPC-157 is not approved by the FDA for human consumption. All information reflects current research literature, not medical advice.
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. Originally isolated from human gastric juice, this compound has shown significant promise in preclinical research for tissue regeneration, wound healing, and gastrointestinal protection.
Molecular Formula: C62H98N16O22
Molecular Weight: 1419.5 g/mol
Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Mechanism of Action
BPC-157 appears to work through several pathways:
- Nitric Oxide Pathway Modulation — Enhances NO synthesis, improving blood flow to damaged tissues
- Growth Factor Upregulation — Increases expression of VEGF, EGF, and HGF
- Cytoskeleton Reorganization — Activates the FAK-paxillin pathway for cellular migration
- Anti-Inflammatory Effects — Modulates TNF-α and IL-6 expression
- Gastroprotective — Maintains GI mucosal integrity via the NO system
Current Research Landscape
Animal Studies (Primary Evidence Base)
| Study | Model | Finding | Ref |
|---|---|---|---|
| Tendon Healing | Rat Achilles | Full recovery 14 days | Chang 2011 |
| Ligament Repair | Rat MCL | Improved strength | Staresinic 2003 |
| Bone Healing | Rabbit | Enhanced callus | Seiwerth 1997 |
| GI Protection | Rat Ulcer | 100% protection | Sikiric 1993 |
| Nerve Regeneration | Rat Sciatic | Improved recovery | Gwyer 2019 |
Human Research Status
As of 2024, BPC-157 has limited human clinical trials:
- No Phase III FDA trials completed
- Anecdotal reports dominate human data
- Phase I safety studies show good tolerability in small cohorts
Critical Note: Most dosing protocols are extrapolated from animal studies, not validated human trials.
Research Protocols by Application
General Tissue Repair Protocol
| Parameter | Specification |
|---|---|
| Dosage | 250-500 mcg |
| Frequency | Once daily |
| Duration | 4-6 weeks |
| Route | Subcutaneous or oral |
Injury-Specific Protocols
Tendon/Ligament Research
- Dosage: 500 mcg daily
- Location: Peri-injury (near but not in the tendon)
- Duration: 6-8 weeks
- Notes: Combine with appropriate loading protocols; BPC-157 enhances but doesn't replace mechanical stimulation
Muscle Tear Recovery
- Dosage: 250-500 mcg daily
- Location: Subcutaneous near injury site
- Duration: 4-6 weeks
- Notes: Best initiated within 48-72 hours post-injury
Gastrointestinal Research
- Dosage: 250-500 mcg daily
- Route: Oral (stable in gastric acid)
- Duration: 2-4 weeks
- Notes: BPC-157 is one of few peptides orally bioavailable
Post-Surgical Recovery
- Dosage: 500 mcg daily
- Duration: 4-8 weeks post-op
- Notes: Coordinate with surgical timeline; anti-inflammatory properties may affect healing cascade
Reconstitution Protocol
Materials Needed
- BPC-157 lyophilized powder (vial)
- Bacteriostatic water (0.9% benzyl alcohol)
- 3mL syringe with 18-20 gauge needle
- Alcohol swabs
- Sharps container
Step-by-Step Reconstitution
- Sanitize — Wipe vial top with alcohol swab, let dry 30 seconds
- Calculate — For 5mg vial + 2mL bacteriostatic water = 2,500 mcg/mL
- Draw — Pull 2mL bacteriostatic water into syringe
- Inject — Slowly inject water down vial side (not directly on powder)
- Dissolve — Gently swirl (never shake) until clear
- Storage — Refrigerate immediately at 2-8°C (36-46°F)
Concentration Reference Table
| Vial Size | BAC Water | Concentration |
|---|---|---|
| 5 mg | 2 mL | 2,500 mcg/mL |
| 5 mg | 2.5 mL | 2,000 mcg/mL |
| 10 mg | 2 mL | 5,000 mcg/mL |
| 10 mg | 4 mL | 2,500 mcg/mL |
Storage & Handling
Reconstituted Peptide
- Temperature: 2-8°C (refrigerator)
- Stability: 2-4 weeks maximum
- Protection: Keep away from light (amber vial or foil wrap)
Lyophilized Powder
- Temperature: -20°C (freezer) for long-term
- Stability: 12+ months properly stored
- Avoid: Repeated freeze-thaw cycles
Travel Considerations
- Use insulated container with ice pack
- Keep under 8°C for up to 24 hours
- Do not freeze reconstituted peptide
Research Considerations & Limitations
Current Knowledge Gaps
- Long-term Safety — No multi-year human safety data
- Optimal Dosing — Animal-to-human conversions are estimates
- Drug Interactions — Limited data on concurrent medication use
- Cancer Risk — Angiogenic properties raise theoretical concerns (unproven)
- Regulatory Status — Banned by WADA; not FDA approved
WADA Status
BPC-157 was added to the World Anti-Doping Agency Prohibited List in 2022 under "S2. Peptide Hormones, Growth Factors, Related Substances." Athletes subject to testing should avoid.
Quality Control Considerations
When sourcing BPC-157 for research:
- ✅ Require third-party HPLC testing
- ✅ Verify ≥98% purity
- ✅ Check for endotoxin levels
- ✅ Confirm proper lyophilization (fluffy cake, not powder)
- ✅ Request Certificate of Analysis (CoA)
Frequently Asked Questions
Is BPC-157 orally bioavailable?
Yes, unlike most peptides, BPC-157 remains stable in gastric acid and shows oral bioavailability in research. This makes it unique for GI applications.
How quickly does it work?
Animal studies show measurable effects within 24-48 hours, with significant tissue changes visible at 1-2 weeks. Human response times vary and are poorly documented.
Can BPC-157 be used with TB-500?
Commonly researched together for synergistic effects on tissue repair. TB-500 addresses systemic inflammation while BPC-157 focuses on localized healing.
What are the side effects?
Animal studies show remarkable safety profiles. Human reports (anecdotal) include mild injection site reactions, temporary fatigue, and rare headaches. No serious adverse events documented in research literature.
How long should a research cycle last?
Standard research protocols range from 4-8 weeks depending on injury severity and tissue type. No established "maximum" duration exists in literature.
Does injection location matter?
Yes — animal studies show localized effects. Injecting near the injury site appears more effective than distant administration for tissue-specific outcomes.
References
- Chang, C.H., et al. (2011). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology.
- Staresinic, M., et al. (2003). "BPC 157 and healing of medial collateral ligament." Surgery Today.
- Seiwerth, S., et al. (1997). "BPC 157's effect on healing of bone defects." Journal of Physiology.
- Sikiric, P., et al. (1993). "The pharmacological properties of the novel peptide BPC 157." European Journal of Pharmacology.
- Gwyer, D., et al. (2019). "BPC 157 and nerve regeneration." Neuropharmacology.
- World Anti-Doping Agency. (2022). Prohibited List.
Research Summary
Strength of Evidence: Moderate (animal models), Low (human trials)
Safety Profile: Excellent in preclinical research
Primary Applications: Soft tissue repair, GI protection, injury recovery
Key Advantage: Oral bioavailability, localized effects
Limitation: Limited human clinical data
Have questions about this protocol? Join our research newsletter for updates on peptide science.
About PeptideDosing.co: We synthesize current research literature on peptide compounds for educational purposes. We do not sell peptides. Always consult qualified researchers and comply with local regulations.